Proof-of-concept study of ficlatuzumab in combination with erlotinib in patients with advanced non-small cell lung cancer

Trial Profile

Proof-of-concept study of ficlatuzumab in combination with erlotinib in patients with advanced non-small cell lung cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 29 Sep 2014

At a glance

  • Drugs Ficlatuzumab (Primary) ; Erlotinib
  • Indications Non-small cell lung cancer
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Sponsors AVEO Oncology; Biodesix
  • Most Recent Events

    • 29 Sep 2014 This confirmatory trial is expected to be initiated by the end of 2014, according to a media release from AVEO Oncology and Biodesix.
    • 16 Apr 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top